CHRU Montpellier, 80, Avenue Augustin Fliche 34295 Montpellier Cedex 5, France.
Diabetes Metab. 2009 Dec;35(6 Pt 2):524-7. doi: 10.1016/S1262-3636(09)73460-3.
Laparoscopic adjustable gastric banding (LAGB) and laparoscopic sleeve gastrectomy (LSG) are two bariatric procedures approved for the management of morbidly obese patients. According to a meta-analysis of all obese patients who underwent bariatric procedures, 11% also had type 2 diabetes mellitus (T2DM) before surgery, and improvement or resolution of this co-morbidity was highlighted in many of the studies. However, the mechanism(s) of action underlying such an effect with the various types of bariatric procedure remain unclear. Also, in terms of weight loss, the most efficient operations are those that come with a high rate of morbidity. This means that the choice of procedure is best done after a multidisciplinary team discussion with the patient in an effort to predict the beneficial effects and risks of each possible procedure. However, for years now, the bariatric team at Montpellier Hospital has preferred either LSG or LGBP as the treatment of choice for morbidly obese patients with T2DM, given the higher rates of failure with LAGB over time compared with the excellent results achieved by both LSG and LGBP in many studies.
腹腔镜可调节胃束带术（LAGB）和腹腔镜袖状胃切除术（LSG）是两种用于治疗病态肥胖患者的减肥手术，已获得批准。根据对所有接受减肥手术的肥胖患者的荟萃分析，术前有 11%的患者还患有 2 型糖尿病（T2DM），许多研究都强调了这种合并症的改善或缓解。然而，各种减肥手术对这种效果的作用机制尚不清楚。此外，就减肥而言，效率最高的手术是那些伴随着高发病率的手术。这意味着在多学科团队与患者进行讨论后，最好选择手术，以预测每种可能手术的有益效果和风险。然而，多年来，蒙彼利埃医院的减肥手术团队一直倾向于将 LSG 或 LGBP 作为治疗伴有 T2DM 的病态肥胖患者的首选方法，因为与 LSG 和 LGBP 在许多研究中取得的出色结果相比，LAGB 的失败率随着时间的推移而升高。
